Calidi Biotherapeutics Appoints Biotech Veteran Eric Poma as CEO to Drive Growth
TL;DR
Calidi Biotherapeutics appoints Eric Poma, PhD, as CEO, leveraging his oncology expertise to advance its innovative cancer therapies and secure a competitive edge in biotech.
Calidi Biotherapeutics enhances its leadership with Dr. Eric Poma as CEO, aiming to systematically progress its stem cell-based cancer treatments through clinical development.
Calidi Biotherapeutics' new CEO, Dr. Eric Poma, is set to drive forward therapies that could significantly improve cancer treatment outcomes and patient safety worldwide.
Discover how Calidi Biotherapeutics' strategic CEO appointment could revolutionize cancer treatment with cutting-edge stem cell and virotherapy technologies.
Found this article helpful?
Share it with your network and spread the knowledge!
Calidi Biotherapeutics Inc. (NYSE American: CLDI), a clinical-stage immuno-oncology company, has announced the appointment of Eric Poma, PhD, as its new chief executive officer and a member of the board of directors. This move is seen as a strategic effort to leverage Dr. Poma's extensive experience in oncology, fundraising, and strategic partnerships to propel the company's next phase of growth.
Dr. Poma's leadership is expected to be instrumental in steering Calidi's pioneering targeted antitumor virotherapies through clinical development and towards commercialization. The company's innovative stem cell-based platforms are designed to enhance the efficacy and safety of oncolytic viruses in treating various oncology indications, including high-grade gliomas and solid tumors.
The appointment underscores Calidi Biotherapeutics' commitment to advancing its dual approach to cancer treatment, which aims not only to treat but potentially prevent metastatic disease. With Dr. Poma at the helm, the company is poised to strengthen its position in the biotech landscape and accelerate the development of its groundbreaking therapies.
Curated from InvestorBrandNetwork (IBN)
